全文获取类型
收费全文 | 2604篇 |
免费 | 233篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 106篇 |
妇产科学 | 65篇 |
基础医学 | 282篇 |
口腔科学 | 52篇 |
临床医学 | 291篇 |
内科学 | 576篇 |
皮肤病学 | 48篇 |
神经病学 | 161篇 |
特种医学 | 134篇 |
外科学 | 239篇 |
综合类 | 44篇 |
预防医学 | 154篇 |
眼科学 | 356篇 |
药学 | 146篇 |
中国医学 | 14篇 |
肿瘤学 | 182篇 |
出版年
2024年 | 3篇 |
2023年 | 32篇 |
2022年 | 40篇 |
2021年 | 88篇 |
2020年 | 38篇 |
2019年 | 73篇 |
2018年 | 109篇 |
2017年 | 62篇 |
2016年 | 81篇 |
2015年 | 81篇 |
2014年 | 111篇 |
2013年 | 146篇 |
2012年 | 188篇 |
2011年 | 179篇 |
2010年 | 113篇 |
2009年 | 122篇 |
2008年 | 199篇 |
2007年 | 162篇 |
2006年 | 130篇 |
2005年 | 102篇 |
2004年 | 93篇 |
2003年 | 70篇 |
2002年 | 81篇 |
2001年 | 23篇 |
2000年 | 26篇 |
1999年 | 36篇 |
1998年 | 36篇 |
1997年 | 42篇 |
1996年 | 44篇 |
1995年 | 45篇 |
1994年 | 36篇 |
1993年 | 26篇 |
1992年 | 34篇 |
1991年 | 30篇 |
1990年 | 27篇 |
1989年 | 24篇 |
1988年 | 15篇 |
1987年 | 9篇 |
1986年 | 12篇 |
1985年 | 16篇 |
1984年 | 10篇 |
1983年 | 8篇 |
1982年 | 13篇 |
1981年 | 6篇 |
1980年 | 10篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1968年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有2857条查询结果,搜索用时 15 毫秒
91.
Robert W. McConkey RANP RNP MSc BSc PG Dip PG Cert Therese Kelly RANP RNP MSc PG Dip PG Cert Rachael Dalton RANP RNT RNP MSc BSc PG Dip Geraldine Rooney cANP RNP BSc PG Dip PG Cert Michelle Healy cANP BSc PG Cert Louise Murphy PhD BSc PG Dip RPN RNT Maura Dowling PhD MSc RGN RNT 《International Journal of Urological Nursing》2023,17(1):78-83
Evidence based practice is essential to advanced practice nursing, enabling the delivery of quality care and improved patient outcomes. As the name suggests, it requires healthcare decisions to be based on the best available and current evidence. Advanced practice nurses need astute critical analysis skills to appraise the evolving literature, and require research skills to lead on scientific inquiry and develop the profession. Yet, advanced practice nurses may not recognize themselves as research leaders. Participation in a journal club can promote evidence-based practice, improve clinician's critical thinking skills, and expose members to different research methodologies, however, nurses continue to face barriers to participation in these clubs. Establishing a clinical-academic partnership appears to be both mutually beneficial for clinicians and academics and is a significant enabler in the sustainability and functioning of the club through sharing expertise and experience. A supportive workplace culture is favourable to research utilization and knowledge translation. This paper outlines the role, practicalities, challenges, and benefits of setting up a hybrid urology journal and research club for advanced practice nurses in a clinical-academic partnership. 相似文献
92.
Wang S Tikellis G Wong N Wong TY Wang JJ 《Diabetes research and clinical practice》2008,81(1):e15-e17
We surveyed 220 patients with diabetic retinopathy attending a tertiary eye hospital in Australia, and found that knowledge of HbA1c, and the proportion achieving target level of <7%, remained low in patients with diabetic retinopathy. These data re-emphasize the gap between clinical guidelines and actual management of patients with diabetes. 相似文献
93.
Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia 总被引:4,自引:0,他引:4
Foon KA; Schroff RW; Bunn PA; Mayer D; Abrams PG; Fer M; Ochs J; Bottino GC; Sherwin SA; Carlo DJ 《Blood》1984,64(5):1085-1093
A phase I clinical trial was initiated to treat patients with stage IV B-derived chronic lymphocytic leukemia (CLL) with the IgG2a murine monoclonal antibody T101. This antibody binds to a 65,000-mol wt (T65) antigen found on normal T lymphocytes, malignant T lymphocytes, and B- derived CLL cells. All of the patients had a histologically confirmed diagnosis of advanced B-derived CLL and were refractory to standard therapy, and more than 50% of their leukemia cells reacted with the T101 antibody in vitro. The patients received T101 antibody two times per week, over two to 50 hours by intravenous administration in 100 mL of normal saline containing 5% human albumin. Twelve patients were treated with a fixed dosage of 1, 10, 50, or 100 mg, and one patient was treated with 140 mg of antibody. It was demonstrated that patients given two-hour infusions of 50 mg developed pulmonary toxicity, with shortness of breath and chest tightness. This toxicity was eliminated when infusions of 50 or 100 mg of T101 were prolonged to 50 hours. All dose levels caused a rapid but transient decrease in circulating leukemia cell counts. In vivo binding to circulating and bone marrow leukemia cells was demonstrated at all dose levels with increased binding at higher dosages. Antimurine antibody responses were not demonstrated in any patients at any time during treatment. Circulating free murine antibody was demonstrated in the serum of only the two patients treated with 100 mg of antibody as a 50-hour infusion and the patient treated with 140 mg of antibody over 30 hours. Antigenic modulation was demonstrated in patients treated at all dose levels but was particularly apparent in patients treated with prolonged infusions of 50 and 100 mg of antibody. We were also able to demonstrate antigenic modulation in lymph node cells, which strongly suggests in vivo labeling of these cells. Overall, T101 antibody alone appears to have a very limited therapeutic value for patients with CLL. The observations of in vivo labeling of tumor cells, antigenic modulation, antibody pharmacokinetics, toxicity, and antimurine antibody formation may be used in the future for more effective therapy when drugs or toxins are conjugated to the antibody. 相似文献
94.
Nguyen Van Hong Alfred Amambua-Ngwa Nguyen Quang Tuan Do Duy Cuong Nguyen Thi Huong Giang Nguyen Van Dung Ta Thi Tinh Nguyen Van Tien Bui Quang Phuc Tran Thanh Duong Anna Rosanas-Urgell Umberto D’Alessandro Jean-Pierre Van Geertruyden Annette Erhart 《Emerging infectious diseases》2014,20(7):1207-1210
Resistance to artemisinin derivatives, the most potent antimalarial drugs currently used, has emerged in Southeast Asia and threatens to spread to Africa. We report a case of malaria in a man who returned to Vietnam after 3 years in Angola that did not respond to intravenous artesunate and clindamycin or an oral artemisinin-based combination. 相似文献
95.
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression 下载免费PDF全文
Hsin‐An Hou Yuan‐Yeh Kuo Jih‐Luh Tang Wen‐Chien Chou Ming Yao Yan‐Jun Lai Chien‐Chin Lin Chien‐Yuan Chen Chieh‐Yu Liu Mei‐Hsuan Tseng Chi‐Fei Huang Ying‐Chieh Chiang Fen‐Yu Lee Ming‐Chih Liu Chia‐Wen Liu Shang‐Yi Huang Bor‐Sheng Ko Shang‐Ju Wu Woei Tsay Yao‐Chang Chen Hwei‐Fang Tien 《American journal of hematology》2014,89(2):181-186
Mutations of the SET binding protein 1 (SETBP1) gene have been identified in patients with myeloid neoplasms, but the clinical relevance of this mutation and its association with other gene mutations in myelodysplastic syndrome (MDS) and the stability during disease progression remains unclear. Mutations in SETBP1 gene at exon 4 were analyzed by polymerase chain reaction and direct sequencing in 430 MDS patients. The results were correlated with clinical features, cytogenetics, gene mutations and treatment outcomes. SETBP1 mutations were identified in 14 (3.3%) of the 430 patients with primary MDS based on the FAB classification and 8 (2.4%) of the 333 patients based on the WHO classification. The SETBP1 mutation was closely associated with higher white blood cell counts, isochromosome of 17q, monosomy 7, and mutations of ASXL1, EZH2 and SRSF2. With a median follow‐up of 43.9 months, MDS patients, based on either the FAB or WHO classification, had a significantly poorer overall survival (OS) if they harbored SETBP1 mutation. Further, SETBP1 mutation was an independent poor prognostic factor for OS (HR = 1.842, CI 95%, 1.1018–3.332, P = 0.043) irrespective of age, sex, and the International Prognostic Scoring System. Sequential analysis showed that the original SETBP1 mutations in the eight SETBP1‐mutated patients studied were retained while two of the 101 SETBP1‐wild patients acquired novel SETBP1 mutations during follow‐ups. The SETBP1 mutation is associated with poor prognosis in MDS. The mutation can be acquired during the clinical course suggesting it may play a role in disease progression. Am. J. Hematol. 89:181–186, 2014. © 2013 Wiley Periodicals, Inc. 相似文献
96.
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution 下载免费PDF全文
Wen‐Chien Chou Yuan‐Yeh Kuo Shang‐Ju Wu Chieh‐Yu Liu Chien‐Yuan Chen Mei‐Hsuan Tseng Chi‐Fei Huang Fen‐Yu Lee Ming‐Chih Liu Chia‐Wen Liu Jih‐Luh Tang Ming Yao Shang‐Yi Huang Szu‐Chun Hsu Bor‐Sheng Ko Woei Tsay Yao‐Chang Chen Hwei‐Fang Tien 《American journal of hematology》2014,89(8):E109-E115
The SF3B1 mutation can be detected in patients with myelodysplastic syndrome (MDS), but the report regarding the association of this mutation with other genetic alterations and its stability during disease progression is limited. In this study, SF3B1 mutations were identified in 10% of total cohort of 479 MDS patients and 61.8% of 34 patients with refractory anemia with ring sideroblasts (RARS). SF3B1 mutations were closely associated with older age, higher platelet counts, lower lactate dehydrogenase levels, good‐risk cytogenetics, and mutations of DNMT3A, but inversely related to ASXL1 mutations. Most SF3B1‐mutated patients had concurrent other genetic alterations, including DNMT3A and RUNX1 mutations. There was no prognostic difference between patients with SF3B1 mutations and those without. Sequential studies in 417 samples from 142 patients demonstrated that all SF3B1‐mutated patients retained the same mutations during disease evolution with the exception of two patients who lost the mutation after allogeneic hematopoietic stem cell transplantation, whereas none of the SF3B1‐wild patients acquired a novel mutation during clinical follow‐ups. In conclusion, the patients with SF3B1 mutations had distinct clinic‐biologic features. SF3B1 mutations, accompanied with other genetic alterations, especially DNMT3A mutations, may play a role in the development of MDS, but have little role in disease progression. Am. J. Hematol. 89:E109–E115, 2014. © 2014 Wiley Periodicals, Inc. 相似文献
97.
IPSS‐R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk‐stratify the patients 下载免费PDF全文
Hsin‐An Hou Chieh‐Yu Liu Chien‐Chin Lin Wen‐Chien Chou Fen‐Yu Lee Ming‐Chih Liu Chia‐Wen Liu Jih‐Luh Tang Ming Yao Chi‐Cheng Li Yuan‐Yeh Kuo Shang‐Yi Huang Bor‐Sheng Ko Chien‐Yuan Chen Szu‐Chun Hsu Chien‐Ting Lin Shang‐Ju Wu Woei Tsay Yao‐Chang Chen Hwei‐Fang Tien 《American journal of hematology》2014,89(9):E142-E149
The revised International Prognostic Scoring System (IPSS‐R) was recently developed to better assess the clinical outcome of adult patients with myelodysplastic syndrome (MDS). In this study, we aimed to investigate the prognostic impact of this new risk model on 555 MDS patients in Taiwan. Generally, the IPSS‐R could discriminate MDS patients regarding risk of leukemia evolution and overall survival in our cohort and it further refined prognostic stratification in all IPSS risk categories. However, we could not find the inter‐group difference between IPSS‐R very low and low risk subgroups in both leukemia‐free survival (LFS) and overall survival (OS). IPSS‐R couldn't distinguish the prognosis between very good and good and between good and intermediate risk cytogenetic categories in OS, and between very good and good and between intermediate and poor cytogenetic‐risk categories in LFS, either. On the other hand, incorporation of monosomal karyotype (MK) into IPSS‐R could further stratify MDS patients with higher‐risk IPSS‐R (intermediate, high and very high risk) into four groups, rather than three groups, with different OS (P < 0.001). Intriguingly, patients receiving allogeneic hematopoietic stem cell transplantation had longer survival than those without in the IPSS‐R high and very high, but not other risk groups. Similarly, patients treated with hypomethylating agents had better survival than those not in the IPSS‐R very high risk group. In conclusion, IPSS‐R can risk‐stratify MDS patients in Taiwan but with some limitations, especially in very low risk category, and MK has additional prognostic value in discriminating MDS patients with higher‐risk IPSS‐R. Am. J. Hematol. 89:E142–E149, 2014. © 2014 Wiley Periodicals, Inc. 相似文献
98.
99.
ALI H.D. Alshehri Sarah O.S. Osman Kevin M. Prise Caoimhghin Campfield PG Turner Suneil FRCR PhD Jain Joe M. OSullivan Aidan J. Cole 《The British journal of radiology》2020,93(1115)
Objectives:The isotope bone scan (IBS) is the gold-standard imaging modality for detecting skeletal metastases as part of prostate cancer staging. However, its clinical utility for assessing skeletal metastatic burden is limited due to the need for subjective interpretation. We designed and tested a novel custom software tool, the Metastatic Bone Scan Tool (MetsBST), aimed at improving interpretation of IBSs, and compared its performance with that of an established software programme.Methods:We used IBS images from 62 patients diagnosed with prostate cancer and suspected bone metastases to design and implement MetsBST in MATLAB by defining thresholds used to identify the texture and size of metastatic bone lesions. The results of MetsBST were compared with those of the commercially available automated Bone Scan Index (aBSI) with regression analysis.Results:There was strong agreement between the MetsBST and aBSI results (R2 = 0.9189). In a subregional analysis, MetsBST quantified the extent of metastatic disease in multiple bone sites in patients receiving multimodality therapy (radium-223 and external beam radiotherapy) to illustrate the differences in bone metastatic response to different treatments.Conclusion:The results of MetsBST and the commercial software aBSI were highly consistent. MetsBST introduces novel clinical utility by its ability to differentiate between the responses of different bone metastases to multimodality therapies.Advances in knowledge:MetsBST reduces the variability in assessment of tumour burden caused by subjective interpretation. Therefore, it is a useful aid to physicians reporting nuclear medicine scans, and may improve decision-making in the treatment of metastatic prostate cancer. 相似文献
100.
Thet Zaw Lam Alfred K. Ranganathan Dwarakanathan Aung Soe Yu Khoo Tien K. 《Clinical rheumatology》2020,39(9):2501-2513
Clinical Rheumatology - This review appraises the current literature on carcinogenic risks in anti-neutrophilic cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). Patients with AAV are... 相似文献